Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cefditoren is a third-generation cephalosporin antibiotic used to treat infections caused by Gram-positive and Gram-negative bacteria, including those resistant to other antibiotics. It is primarily indicated for community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, pharyngitis, tonsillitis, uncomplicated skin and skin structure infections, and otitis media. Cefditoren is administered orally as the prodrug cefditoren pivoxil, which is hydrolyzed in the body to its active form. Its mechanism of action involves inhibiting bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to bactericidal activity. Cefditoren demonstrates stability against many common beta-lactamases[4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cefditoren.